clinical trial · NCT05592418
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
Post COVID-19 ConditionLong COVIDRintatolimodPlacebo / Normal Saline
brief summary
The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.
started
Jun 30, 2023
primary completion
Nov 17, 2023
completion
Nov 30, 2023
last updated
Jan 22, 2025
detailed description
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the efficacy and safety of Ampligen® in patients experiencing the Post-COVID Condition of fatigue. Patients will be randomized 1:1 to receive twice weekly IV infusions of Ampligen® or placebo.
official title
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ampligen® in Patients With Post-COVID Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol